PF-06817024
Phase 1Biologic
PfizerPF-06817024 is one of 32 biologic programs targeting Chronic Rhinosinusitis With Nasal Polyps. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Chronic Rhinosinusitis With Nasal Polyps
#DrugCompanyPhaseTrials
1Xolair
RochePhase 3
Tezspire
AstraZenecaPhase 3
Stapokibart
CChengdu Kangnuoxing Biopharma,Inc.
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
EXDENSUR
GGlaxo Dba Glaxosmithkline
Phase 3
Sporanox
SSebela Pharmaceuticals Development LLC
Phase 3
Asmanex
NovartisPhase 2
Itepekimab AI
SanofiPhase 3
Medrol
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PF-06817024. EMBL-EBI & Wellcome Sanger Institute.
- [4]